Compare CAAS & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAS | CRBU |
|---|---|---|
| Founded | N/A | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.9M | 138.3M |
| IPO Year | 2025 | 2021 |
| Metric | CAAS | CRBU |
|---|---|---|
| Price | $5.00 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 19.3K | ★ 1.1M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | $3.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.00 | $1.25 |
| 52 Week High | $5.64 | $3.53 |
| Indicator | CAAS | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 33.15 |
| Support Level | $4.39 | N/A |
| Resistance Level | $5.00 | $1.76 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 0.87 | 6.94 |
China Automotive Systems Inc is a holding company. The firm, through its subsidiary, is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series of power steering models, including rack and pinion power steering, integral power steering, electronic power steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.